{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:42:27Z","timestamp":1790523747262,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"am","delay-in-days":255,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jbspin.2021.105164","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T04:38:11Z","timestamp":1613882291000},"page":"105164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Antigen-specific tolerance approach for rheumatoid arthritis: Past, present and future"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2838-5892","authenticated-orcid":false,"given":"Audrey","family":"Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Fusil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8842-3726","authenticated-orcid":false,"given":"Fran\u00e7ois-Lo\u00efc","family":"Cosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2021.105164_bib0330","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jbspin.2021.105164_bib0335","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0167-4889(91)90010-U","article-title":"Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts","volume":"1094","author":"Wright","year":"1991","journal-title":"Biochim Biophys Acta \u2013 Mol Cell Res"},{"key":"10.1016\/j.jbspin.2021.105164_bib0340","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/BOR.0000000000000638","article-title":"Porphyromonas gingivalis and rheumatoid arthritis","volume":"31","author":"Perricone","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0345","first-page":"9","article-title":"The impact of cigarette smoking on risk of rheumatoid arthritis: a narrative review","author":"Ishikawa","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jbspin.2021.105164_bib0350","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/annrheumdis-2014-207182","article-title":"Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis","volume":"75","author":"Kerkman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105164_bib0355","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3899\/jrheum.131375","article-title":"Anticyclic citrullinated peptide antibodies in rheumatoid and non-rheumatoid rheumatic disorders: experience with 1162 patients","volume":"41","author":"Payet","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0360","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105164_bib0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.0105-2896.2009.00853.x","article-title":"Antibodies to citrullinated proteins: molecular interactions and arthritogenicity","volume":"233","author":"Uysal","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jbspin.2021.105164_bib0370","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/BOR.0000000000000452","article-title":"Rheumatoid arthritis and citrullination","volume":"30","author":"Darrah","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0375","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jbspin.2019.11.009","article-title":"Origins of rheumatoid arthritis","volume":"87","author":"Boissier","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2021.105164_bib0380","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.25036","article-title":"Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients","volume":"62","author":"Snir","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105164_bib0385","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2021.105164_bib0390","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jbspin.2008.08.002","article-title":"Regulatory T cells (Treg) in rheumatoid arthritis","volume":"76","author":"Boissier","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2021.105164_bib0395","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1186\/ar1169","article-title":"Induction of IL-10-producing CD4+ CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen","volume":"6","author":"Min","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0400","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1073\/pnas.91.14.6688","article-title":"Induction of anergy or active suppression following oral tolerance is determined by antigen dosage","volume":"91","author":"Friedman","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jbspin.2021.105164_bib0405","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri2153","article-title":"Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease","volume":"7","author":"Miller","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0410","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clim.2006.08.004","article-title":"Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis","volume":"122","author":"Zhu","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0415","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.4049\/jimmunol.155.7.3653","article-title":"Oral administration of an immuno-dominant human collagen peptide modulates collagen-induced arthritis","volume":"155","author":"Khare","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0420","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1749-6632.1996.tb21138.x","article-title":"Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis","volume":"778","author":"Trentham","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jbspin.2021.105164_bib0425","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1126\/science.8378772","article-title":"Effects of oral administration of type II collagen on rheumatoid arthritis","volume":"261","author":"Trentham","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jbspin.2021.105164_bib0430","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/art.1780390106","article-title":"Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomised trial","volume":"39","author":"Sieper","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105164_bib0435","doi-asserted-by":"crossref","first-page":"R180","DOI":"10.1186\/ar2870","article-title":"A multicentre, double-blind, randomised, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis","volume":"11","author":"Wei","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0440","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/1529-0131(199802)41:2<290::AID-ART13>3.0.CO;2-R","article-title":"Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicentre, double-blind, placebo-controlled trial","volume":"41","author":"Barnett","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105164_bib0445","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/1529-0131(200109)44:9<1993::AID-ART347>3.0.CO;2-A","article-title":"Control of rheumatoid arthritis by oral tolerance","volume":"44","author":"Choy","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105164_bib0450","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1073\/pnas.83.19.7443","article-title":"Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen","volume":"83","author":"Nagler-Anderson","year":"1986","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jbspin.2021.105164_bib0455","first-page":"763","article-title":"Gastric administration of recombinant 65 kDa heat shock protein delays the severity of type II collagen induced arthritis in mice","volume":"25","author":"Jorgensen","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0460","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2249.1996.tb08289.x","article-title":"Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope","volume":"103","author":"Staines","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0465","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1006\/jaut.1999.0320","article-title":"Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen","volume":"13","author":"Garcia","year":"1999","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jbspin.2021.105164_bib0470","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/intimm\/dxh075","article-title":"Vaccination with an immuno-dominant peptide of bovine type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis","volume":"16","author":"Honda","year":"2004","journal-title":"Int Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0475","first-page":"110","article-title":"Identification and characterisation of a major tolerogenic T-cell epitope of type II collagen that suppresses arthritis in B10.RIII mice","volume":"86","author":"Miyahara","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.jbspin.2021.105164_bib0480","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/cgt.2008.68","article-title":"Growth inhibition of an established A431 xenograft tumour by a full-length anti-EGFR antibody following gene delivery by AAV","volume":"16","author":"Ho","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0485","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.vaccine.2008.11.090","article-title":"Construction and characterisation of a novel DNA vaccine that is potent antigen-specific tolerising therapy for experimental arthritis by increasing CD4+ CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines","volume":"27","author":"Xinqiang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jbspin.2021.105164_bib0490","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/art.1780371009","article-title":"Therapeutic effect of recombinant vaccinia virus expressing the 60-kd heat-shock protein on adjuvant arthritis","volume":"37","author":"Antonio L\u00f3pez-Guerrero","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105164_bib0495","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar3074","article-title":"Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II","volume":"12","author":"Tang","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/345092","article-title":"Antigen-specific gene therapy after immunisation reduces the severity of collagen-induced arthritis","volume":"2013","author":"Eneljung","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0505","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/mt.2009.299","article-title":"Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis","volume":"17","author":"Gjertsson","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0510","doi-asserted-by":"crossref","first-page":"e0154630","DOI":"10.1371\/journal.pone.0154630","article-title":"Gene therapy induces antigen-specific tolerance in experimental collagen-induced arthritis","volume":"11","author":"Tengvall","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jbspin.2021.105164_bib0515","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1615\/CritRevImmunol.v27.i4.40","article-title":"PART III. Autoimmunity: an altered peptide ligand of type II collagen suppresses autoimmune arthritis","volume":"27","author":"Myers","year":"2007","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0520","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.molimm.2008.10.016","article-title":"A novel recombinant peptide containing only two T-cell tolerance epitopes of chicken type II collagen that suppresses collagen-induced arthritis","volume":"46","author":"Xi","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0525","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.4049\/jimmunol.1402457","article-title":"Immune tolerance induction with multiepitope peptide derived from citrullinated autoantigens attenuates arthritis manifestations in adjuvant arthritis rats","volume":"194","author":"Gertel","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0530","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.4049\/jimmunol.1400986","article-title":"DEC205+ dendritic cell-targeted tolerogenic vaccination promotes immune tolerance in experimental autoimmune arthritis","volume":"194","author":"Spiering","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0535","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.intimp.2009.12.016","article-title":"CEL-2000: a therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine\/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model","volume":"10","author":"Zimmerman","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0540","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/gt.2013.65","article-title":"Enhanced anti-tumour immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fibre structures","volume":"21","author":"Kim","year":"2014","journal-title":"Gene Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0545","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.4049\/jimmunol.0802972","article-title":"Antigen-specific suppression of inflammatory arthritis using liposomes","volume":"182","author":"Capini","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0550","doi-asserted-by":"crossref","first-page":"e126025","DOI":"10.1172\/jci.insight.126025","article-title":"PD-L1 and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease","volume":"4","author":"Galea","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jbspin.2021.105164_bib0555","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1021\/acschembio.8b01018","article-title":"Exploiting CD22 to selectively tolerise autoantibody producing B-cells in rheumatoid arthritis","volume":"14","author":"Bednar","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0560","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13075-016-0918-0","article-title":"In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles","volume":"18","author":"Pozsgay","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0565","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cei.12038","article-title":"Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?: current status of tolDC therapy","volume":"172","author":"Hilkens","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0570","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3389\/fimmu.2019.02068","article-title":"Matured tolerogenic dendritic cells effectively inhibit autoantigen specific CD4+ T cells in a murine arthritis model","volume":"10","author":"Jansen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0575","doi-asserted-by":"crossref","first-page":"e0131152","DOI":"10.1371\/journal.pone.0131152","article-title":"Antigen-specific tolerogenic dendritic cells ameliorate the severity of murine collagen-induced arthritis","volume":"10","author":"Ning","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jbspin.2021.105164_bib0580","doi-asserted-by":"crossref","first-page":"290ra87","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jbspin.2021.105164_bib0585","series-title":"Phase 1 study of immunotherapy using autoantigen- loaded dendritic cells in patients with anti-citrullinated peptide antigen positive rheumatoid arthritis","author":"Joo","year":"2014"},{"key":"10.1016\/j.jbspin.2021.105164_bib0590","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105164_bib0595","first-page":"1","article-title":"DC-based immunotherapy combined with low-dose methotrexate effective in the treatment of advanced CIA in mice","volume":"2015","author":"Park","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jbspin.2021.105164_bib0600","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2249.1998.00529.x","article-title":"B cell-deficient mice do not develop type II collagen-induced arthritis (CIA)","volume":"111","author":"Svensson","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0605","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"87","author":"Mok","year":"2013","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0610","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13075-016-1037-7","article-title":"Collagen epitope expression on B cells is sufficient to confer tolerance to collagen-induced arthritis","volume":"18","author":"Andersson","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0615","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar4567","article-title":"Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis","volume":"16","author":"Asnagli","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105164_bib0620","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1172\/JCI66938","article-title":"Amelioration of arthritis through mobilisation of peptide-specific CD8+ regulatory T cells","volume":"123","author":"Leavenworth","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jbspin.2021.105164_bib0625","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jbspin.2021.105164_bib0630","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jbspin.2021.105164_bib0635","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V126.23.294.294","article-title":"BAR-CD8 T-cell mediated targeted killing of inhibitor producing FVIII-specific B cells","volume":"126","author":"Parvathaneni","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2021.105164_bib0640","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fimmu.2019.00203","article-title":"Humanised mouse models of rheumatoid arthritis for studies on immunopathogenesis and preclinical testing of cell-based therapies","volume":"10","author":"Schinnerling","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2021.105164_bib0645","doi-asserted-by":"crossref","first-page":"e49731","DOI":"10.1371\/journal.pone.0049731","article-title":"Disease-dependent local IL-10 production ameliorates collagen-induced arthritis in mice","volume":"7","author":"Henningsson","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jbspin.2021.105164_bib0650","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1007\/s00018-020-03486-y","article-title":"Building sophisticated sensors of extracellular cues that enable mammalian cells to work as \u201cdoctors\u201d in the body","volume":"77","author":"Kojima","year":"2020","journal-title":"Cell Mol Life Sci"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:27:56Z","timestamp":1761150476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X21000361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1297319X21000361"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105164","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigen-specific tolerance approach for rheumatoid arthritis: Past, present and future","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105164"}}